Price movement over the last 24 hours
ADMA Biologics Inc vs Eos Energy Enterprises Inc — how do they compare? ADMA Biologics Inc trades at $9.19 (market cap $2.13B), while Eos Energy Enterprises Inc trades at $4.49 (market cap $1.68B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EOSE | |
|---|---|---|
Market Cap | $2.13B | $1.68B |
Sector | Health | Energy |
52-Week High | $20.38 | $19.19 |
52-Week Low | $7.60 | $4.40 |
Enterprise Value | $2.20B | $1.91B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
EOSE trades at $5.06, down 3.25% today, amid a bearish technical signal despite a recent Q1 2026 earnings beat. The company shows rapid revenue growth but deep losses, with a net income margin of -296.13% in 2026. Recent news highlights progress in its Frontier Power USA venture and new supply agreements, yet cash flow remains negative from operations, relying on financing.
The outlook is mixed: analyst consensus is a Buy with a $8.33 price target, signaling potential upside, but high execution risk persists given substantial losses and a debt-to-asset ratio of 91.87%. Investors face volatility from operational cash burn against growth initiatives in the competitive energy storage market.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →